|
Clinical
Characteristics
|
XBB.1.16*
|
Other Omicron Lineages
|
Grand Total
|
p-value
|
|
XBB.1.16
|
XBB.1.16.1
|
|
History of prior COVID-19 infection
|
0.010
|
|
Present
|
21 (10.7%)
|
9 (11.3%)
|
23 (20.9%)
|
53 (13.7%)
|
|
|
Absent
|
175 (89.3%)
|
71 (88.7%)
|
87 (79.1%)
|
333 (86.3%)
|
|
|
Symptom status at the time of acute infection
|
0.125
|
|
Asymptomatic
|
16 (8.2%)
|
6 (7.5%)
|
4 (3.6%)
|
26 (6.7%)
|
|
|
Symptomatic
|
180 (91.8%)
|
74 (92.5%)
|
106 (96.4%)
|
360 (93.3%)
|
|
|
Presence of any comorbidity
|
0.114
|
|
No comorbidity
|
161 (82.1%)
|
66 (82.5%)
|
97 (88.2%)
|
324 (83.9%)
|
|
|
Presence of one comorbid condition
|
24 (12.3%)
|
10 (12.5%)
|
12 (10.9%)
|
46 (11.9%)
|
|
|
Presence of two or more comorbid conditions
|
11 (5.6%)
|
4 (5.0%)
|
1 (0.9%)
|
16 (4.2%)
|
|
|
Initial presenting symptoms
|
|
|
Fever
|
127 (64.8%)
|
58 (72.5%)
|
76 (69.1%)
|
261 (67.6%)
|
0.696
|
|
Cough
|
85 (43.4%)
|
31 (38.8%)
|
39 (35.5%)
|
155 (40.2%)
|
0.234
|
|
Rhinorrhoea
|
67 (34.2%)
|
26 (32.5%)
|
39 (35.5%)
|
132 (34.2%)
|
0.742
|
|
Fatigue
|
27 (13.8%)
|
12 (15.0%)
|
19 (17.3%)
|
58 (15.0%)
|
0.435
|
|
Body ache
|
28 (14.3%)
|
12 (15.0%)
|
13 (11.8%)
|
53 (13.7%)
|
0.491
|
|
Headache
|
22 (11.2%)
|
6 (7.5%)
|
16 (14.5%)
|
44 (11.4%)
|
0.219
|
|
Breathlessness
|
17 (8.7%)
|
6 (7.5%)
|
4 (3.6%)
|
27 (7.0%)
|
0.102
|
|
Sore Throat
|
7 (3.6%)
|
9 (11.3%)
|
11 (10.0%)
|
27 (7.0%)
|
0.144
|
|
Diarrhoea
|
7 (3.6%)
|
3 (3.8%)
|
1 (0.9%)
|
11 (2.8%)
|
0.190
|
|
Vomiting
|
3 (1.5%)
|
2 (2.5%)
|
3 (1.8%)
|
7 (1.8%)
|
1.000
|
|
Chest Pain
|
3 (1.5%)
|
0
|
1 (0.9%)
|
4 (1.0%)
|
1.000
|
|
Loss of taste and smell
|
4 (2.0%)
|
0
|
2 (1.8%)
|
6 (1.6%)
|
1.000
|
|
Increased Sweating
|
0
|
2 (2.5%)
|
2 (0.7%)
|
3 (0.8%)
|
-
|
|
Reduced appetite
|
3 (1.5%)
|
0
|
0
|
3 (0.8%)
|
-
|
|
Type of quarantine
|
0.018
|
|
Home quarantine
|
145 (74.0%)
|
60 (75.0%)
|
94 (85.5%)
|
299 (77.5%)
|
|
|
Institutional quarantine/ Hospitalization
|
51 (26.0%)
|
20 (25.0%)
|
16 (14.5%)
|
87 (22.5%)
|
|
|
Treatment
|
|
|
a. Home Isolated
|
0.433
|
|
No treatment needed
|
3 (2.1%)
|
4 (6.7%)
|
1 (1.1%)
|
8 (2.7%)
|
|
|
Needed Conservative treatment only
|
141 (97.2%)
|
56 (93.3%)
|
92 (97.8%)
|
289 (96.6%)
|
|
|
Antiviral treatment taken
|
1 (0.7%)
|
0
|
1 (1.1%)
|
2 (0.7%)
|
|
|
b. Institutional quarantine/ Hospitalization
|
0.633
|
|
Needed Conservative treatment only
|
34 (66.7%)
|
12 (60.0%)
|
10 (62.5%)
|
56 (64.4%)
|
|
|
Needed Supplemental oxygen
|
17 (33.3%)
|
7 (35.0%)
|
6 (37.5%)
|
30 (34.5%)
|
|
|
Mask
|
14 (82.3%)
|
7 (100%)
|
5 (83.3%)
|
26 (86.7%)
|
|
|
Intubation
|
3 (17.7%)
|
0
|
1 (16.7%)
|
4 (13.3%)
|
|
|
Needed antiviral/steroids/
Immunomodulatory drugs, along with oxygen therapy
|
0
|
1 (5.0%)
|
0
|
1 (1.1%)
|
|
|
Outcome of disease
|
0.449
|
|
Alive
|
192 (98.0%)
|
77 (96.2%)
|
109 (99.1%)
|
378 (97.9%)
|
|
|
Home quarantine
|
145 (75.5%)
|
59 (76.6%)
|
94 (86.2%)
|
298 (78.8%)
|
|
|
Institutional quarantine/ Hospitalization
|
47 (24.5%)
|
18 (23.4%)
|
15 (13.8%)
|
80 (21.2%)
|
|
|
Dead
|
4 (2.0%)
|
3 (3.8%)
|
1 (0.9%)
|
8 (2.1%)
|
|
|
Home quarantine
|
0
|
1 (33.3%)
|
0
|
1 (12.5%)
|
|
|
Institutional quarantine/ Hospitalization
|
4 (100%)
|
2 (66.7%)
|
1 (100%)
|
7 (87.5%)
|
|
|
Vaccination Status
|
0.288
|
|
Not vaccinated
|
18 (9.2%)
|
05 (6.2%)
|
13 (11.8%)
|
36 (9.3%)
|
|
|
Vaccinated
|
178 (90.8%)
|
75 (93.8%)
|
97 (88.2%)
|
350 (90.7%)
|
|
|
Vaccinated with one dose
|
13 (7.3%)
|
2 (2.7%)
|
2 (2.1%)
|
17 (4.9%)
|
|
|
Vaccinated with two doses
|
144 (80.9%)
|
52 (69.3%)
|
69 (71.1%)
|
265 (75.7%)
|
|
|
Vaccinated with precautionary dose
(Booster dose)
|
21 (11.8%)
|
21 (28.0%)
|
26 (26.8%)
|
68 (19.4%)
|
|
